University of Arkansas for Medical Sciences/Myeloma Institute
Welcome,         Profile    Billing    Logout  
 2 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Morgan, Gareth
NCT00572169: UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

Checkmark P3 data
Jun 2012 - Jun 2012: P3 data
Active, not recruiting
3
177
US
Velcade, Bortezomib, PS-341, Thalidomide, Thalomid, Dexamethasone, Decadron, NSC-34521, Adriamycin, Doxorubicin, NSC-123127, Cisplatin, Cis-diamminedichloroplatinum [CDDP], Platinol, NSC-119875, Cyclophosphamide, Cytoxan, NSC-26271, Etoposide, VP-16), Vepesid®, Ethylidene-Lignan P., NSC-141540
University of Arkansas
Multiple Myeloma
08/25
08/25
NCT04887259 / 2020-004583-26: Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

Checkmark Efficacy data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Dec 2022 - Dec 2022: Efficacy data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Checkmark Safety data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Dec 2022 - Dec 2022: Safety data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Checkmark First patient dosing for P1/2a for relapsed refractory CLL
More
Terminated
1
16
Europe, US
LAVA-051, Interleukin 2
Lava Therapeutics, LAVA Therapeutics N.V., LAVA Therapeutics B.V.
Chronic Lymphocytic Leukemia, Multiple Myeloma, Acute Myeloid Leukemia
09/23
09/23
ASCENT ASD, NCT04591392: Safety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD

Recruiting
N/A
250
Europe, US
reSept ASD Occluder
atHeart Medical
Heart Septal Defect, Heart Septal Defects, Atrial, Heart Defects, Congenital, Cardiovascular Abnormalities, Cardiovascular Diseases, Heart Diseases, Congenital Abnormalities
12/26
12/30
NCT05006404: Autus Valve Pivotal Study

Recruiting
N/A
50
US
Pulmonary Valve Replacement Surgery
Autus Valve Technologies, Inc.
Congenital Heart Disease
08/26
02/36
NCT05077774: Harmony TPV Post-Approval Study

Recruiting
N/A
150
Canada, US
Harmony TPV System, Model Numbers: HARMONY-22, HARMONY-25, and HARMONY-DCS
Medtronic Cardiovascular
Congenital Heart Disease, Tetrology of Fallot, RVOT Anomaly, Pulmonary Regurgitation
10/25
03/35
PIVOTAL, NCT05547165: Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants

Recruiting
N/A
240
US
Percutaneous Patent Ductus Arteriosus Closure (PPC), Responsive Management Intervention, Echocardiogram, cardiac
Nationwide Children's Hospital, National Institutes of Health (NIH), Abbott, University of Pittsburgh, University of Bristol, Dartmouth College, University of Iowa, Emory University, Cedars-Sinai Medical Center, Children's Hospital Los Angeles, National Heart, Lung, and Blood Institute (NHLBI)
Ductus Arteriosus, Patent
02/26
02/26
NCT04034498: A Multicenter, International, Follow-up Study to Monitor the Efficacy and Safety of the Occlutech® PmVSD Occluder in Patients With Perimembranous Ventricular Septal Defects

Active, not recruiting
N/A
50
Europe, RoW
Occlutech International AB
Perimembranous Ventricular Septal Defect
06/26
07/26

Download Options